Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
September 07 2021 - 8:30AM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in
precision genetic medicine for rare diseases, today announced
fifteen recipients of Route 79, The Duchenne Scholarship Program.
This is the fourth year of the scholarship program, which was
created to recognize exceptional individuals living with Duchenne
muscular dystrophy as they pursue their post-secondary education.
We share this good news on World Duchenne Awareness Day, a day when
much of the global community is focused on this year’s special
theme ‘Adult Life & Duchenne.’ Recipients of this scholarship
were chosen by an independent selection committee composed of
Duchenne community members, who consider each applicant’s community
involvement and a personal essay. Each student will receive a
scholarship of up to $5,000.
“On behalf of Sarepta
and the selection committee it is my pleasure to announce the 2021
recipients of Route 79, The Duchenne Scholarship Program and
congratulate them on this achievement. The awardees have shown
tremendous determination, resiliency and dedication to their
academic pursuits, even in the face of the challenges and
disruptions resulting from the ongoing pandemic,” said Diane Berry,
Sarepta’s Senior Vice President of Global Health Policy, Government
and Patient Affairs. “We are honored to support these young adults
in their journey through higher education, and we wish them new
opportunities and success in the school year ahead. I also would
like to express my appreciation to the selection committee, the
members of which gave so generously of their time in reviewing the
applications and essays.”
2021 Named Recipients - Route 79, The
Duchenne Scholarship Program
Porter Aydelotte, Saddleback College
Brett Dettmer, University of
Missouri-Columbia
Billy Ellsworth, Community College of Allegheny
County
Aiden Fecteau, Eastern Connecticut State
University
Bryson Foster, University of North Carolina at
Charlotte
Yuvaraj Gambhir, University of Pennsylvania
Ethan Higginbotham, Wichita State University
Brian Le, Stanford University
Jake Marrazzo, Wheaton College
Darrel Nicklow, Jr., Florida Gulf Coast
University
Spencer Poole, Saint Joseph’s College-Suffolk
Campus
James Scott, University of San Diego
Parker Strobeck, North Arkansas College
Tayjus Surampudi, Harvard University
Joseph Ware, Liberty University
In addition to application review by the
independent committee, submissions are de-identified for the voting
panel with no indication of whether the candidate has received, or
plans to receive, a Sarepta therapy.
About Route 79, The Duchenne
Scholarship Program
Route 79, The Duchenne Scholarship Program
is designed to help students diagnosed with Duchenne muscular
dystrophy (Duchenne) pursue their post-high school educational
goals. There are 79 exons in the dystrophin gene impacted by
Duchenne, and the route traveled by every person with Duchenne is
distinct. Sarepta’s goal through this program is to acknowledge and
support individuals with Duchenne who are mapping out their future
via educational pursuits. Additional information is available at
https://www.sarepta.com/route79.
About Sarepta
Therapeutics
Sarepta is on an
urgent mission: engineer precision genetic medicine for rare
diseases that devastate lives and cut futures short. We hold
leadership positions in Duchenne muscular dystrophy (DMD) and
limb-girdle muscular dystrophies (LGMDs), and we currently have
more than 40 programs in various stages of development. Our vast
pipeline is driven by our multi-platform Precision Genetic Medicine
Engine in gene therapy, RNA and gene editing. For more information,
please visit www.sarepta.com or follow us on Twitter,
LinkedIn, Instagram and Facebook.
Internet
Posting of Information
We routinely post
information that may be important to investors in the 'For
Investors' section of our website at www.sarepta.com. We
encourage investors and potential investors to consult our website
regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Investor Contact: Ian Estepan,
617-274-4052iestepan@sarepta.com
Media Contact: Tracy Sorrentino,
617-301-8566tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2023 to Apr 2024